UBX1325
Modify Date: 2025-08-25 13:50:36
UBX1325 structure
|
Common Name | UBX1325 | ||
|---|---|---|---|---|
| CAS Number | 2271269-01-1 | Molecular Weight | 1159.69 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C53H59ClF3N6O10PS3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of UBX1325UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR)[1]. |
| Name | UBX1325 |
|---|
| Description | UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR)[1]. |
|---|---|
| Related Catalog | |
| In Vitro | UBX1325 leads to a decrease in the anti-apoptotic Bcl-xL:Bim complex in retina by intravitreal (IVT) injection administration in oxygen induced retinopathy (OIR) C57BL/6 mice model[1]. UBX1325 can cause a decrease in retinal vascular permeability and promote retinal neovascularization in streptozotocin (STZ)-induced retinopathy mice model[1]. |
| References |
| Molecular Formula | C53H59ClF3N6O10PS3 |
|---|---|
| Molecular Weight | 1159.69 |